文献速递肾癌与肾肿瘤前列腺癌

TACTICAL1试验方案:肺癌筛查同时行腹部CT筛查肾癌及其他腹部疾病:随机对照预试验

TACTICAL1 Trial Protocol: Targeted Abdominal CT in Conjunction with Lung Cancer Screening to Identify Kidney Cancer and Other Abdominal Conditions: A Randomised Controlled Pilot Study.
PubMed 文献 · Eur Urol Oncol · 2026-09-22

TACTICAL1为在英国约克郡开展的随机对照预试验,在55-70岁高危吸烟者首次肺癌筛查(LCS)时,随机邀请加做腹部平扫CT(ANCCT),并设两次随机化。主要评估邀请干预对LCS参与率的影响、整群随机可行性、扫描通量影响及可接受性,为未来大规模RCT设计提供依据。

要点

  • 在肺癌筛查中同步加做腹部平扫CT在真实世界具可行性和成本效益潜力。
  • 试验含邀请层面和扫描层面两次随机化,整群随机评估可行性。
  • 预试验不评估筛查发现病变的患病率、分期或生存,旨在为大规模RCT设计铺路。

核心结论

  • 在肺癌筛查中加做腹部平扫CT的整合筛查模型在真实世界中有望可行且具成本效益潜力,需通过预试验验证并设计未来大规模RCT。

研究设计与样本

  • TACTICAL1为嵌入过程评估的预试验,受试者为英国约克郡参加首轮肺癌筛查、年龄55-70岁、肺癌高风险的曾吸烟者。
  • 个体水平1:1随机分为仅收到LCS邀请信(邀请对照)或收到LCS邀请信并可能加做ANCCT(邀请干预)。
  • 邀请干预组再整群1:1随机分为仅提供胸部低剂量CT(扫描对照)或胸部低剂量CT联合ANCCT(扫描干预)。

主要发现

  • 原文未报告预试验结果,仅描述四个主要终点:邀请干预是否影响LCS参与率、整群随机可行性、加做ANCCT对扫描通量的影响、参与者与筛查人员的可接受性。

关键数值与推荐

  • 原文未报告具体数值、阈值或推荐条款。

临床怎么用

  • 预试验结果将用于指导未来大规模RCT的设计,以评估分期迁移、更早发现和潜在生存获益等结局。

局限性

  • TACTICAL1为预试验,不旨在评估筛查发现病变的患病率或分期,也不评估生存。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Screening for kidney cancer and other serious abdominal conditions in conjunction with lung cancer screening (LCS) is potentially feasible and cost-effective. Targeted Abdominal CT in Conjunction with Lung Cancer Screening (TACTICAL1) aims to pilot this integrated screening model in a real-world setting to inform a future large-scale randomised controlled trial (RCT). TACTICAL1 is a pilot study, with embedded process evaluation, of adding abdominal noncontrast computed tomography (CT; ANCCT) to low-dose CT (LDCT) thorax amongst ever smokers aged 55-70 yr at high risk of lung cancer who were attending the first round of LCS in Yorkshire, UK. There are two points of randomisation. First, participants are randomised 1:1 at the individual level to receive either an LCS invitation letter (invitation control) or an invitation letter for LCS with potential for an additional ANCCT (invitation intervention). Participants in the latter group are then cluster randomised 1:1 to be offered either LDCT thorax alone (scan control) or both LDCT thorax and ANCCT (scan intervention). TACTICAL1 has four primary endpoints and will assess the following: (1) whether the invitation intervention affects LCS uptake, (2) feasibility of cluster randomisation, (3) impact of adding ANCCT to LCS on scanning throughput, and (4) acceptability to participants and screening staff. Strengths include the real-world setting and robust randomisation. TACTICAL1 is a pilot study; therefore, it does not aim to evaluate the prevalence or stage of screen-detected findings nor survival. TACTICAL1 will inform the development of a future large-scale RCT assessing outcomes such as stage shift, earlier detection, and potential survival benefits. A previous study showed that it is possible to offer an additional computed tomography scan of the abdomen at the same time as lung cancer screening. This extra scan may help detect kidney cancer and other serious abdominal conditions early. TACTICAL1 is a pilot research study in which people are randomly assigned to different groups. Its aim is to test how this combined screening approach could work in practice. The results will help design a much larger future study to find out whether combining these scans can save lives.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Rossi SH, Kitt J, Clark M, et al. TACTICAL1 Trial Protocol: Targeted Abdominal CT in Conjunction with Lung Cancer Screening to Identify Kidney Cancer and Other Abdominal Conditions: A Randomised Controlled Pilot Study. Eur Urol Oncol. 2026. PMID: 42919785. doi:10.1016/j.euo.2026.08.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。